LivaNova PLC logo LIVN - LivaNova PLC

Price: -- -- | CONSENSUS: Buy DETAILS
STRONG
BUY
0
BUY 11
HOLD 3
SELL 1
STRONG
SELL
0
| PRICE TARGET: $93.33 DETAILS
HIGH: $105.00
LOW: $85.00
MEDIAN: $92.50
CONSENSUS: $93.33
UPSIDE: 18.98%

About LivaNova PLC (https://www.livanova.com)

LivaNova PLC is a global medical technology company dedicated to developing, manufacturing, and marketing a variety of therapeutic solutions. The company operates through three key segments. Its Cardiopulmonary division provides essential products for heart-lung procedures, such as oxygenators, heart-lung machines, and various perfusion systems. The Neuromodulation segment is known for its VNS Therapy System, an implantable device that delivers vagus nerve stimulation to treat drug-resistant epilepsy, difficult-to-treat depression, and obstructive sleep apnea. This segment is also advancing the VITARIA System, which employs VNS for heart failure, through clinical development. The Advanced Circulatory Support segment offers temporary life support solutions, including both cardiopulmonary and respiratory support technologies. LivaNova serves a wide range of medical professionals, including perfusionists, neurologists, neurosurgeons, and other physicians, as well as hospitals and healthcare providers. The company's products are distributed globally through both its direct sales force and independent distributors. Additionally, LivaNova has a research collaboration with Verily aimed at discovering clinical biomarkers for depression. Founded in 1987, the company is headquartered in London, United Kingdom.

Key Executives

NAME TITLE DOB SALARY
Vladimir A. Makatsaria Chief Executive Officer & Director 1973 $2,369,126 USD
Alex Shvartsburg Chief Financial Officer 1970 $1,120,910 USD
Natalia Sergeyevna Kozmina Chief Human Resources Officer 1971 $1,089,048 USD
Ahmet Tezel Chief Innovation Officer 1975 $1,067,305 USD
Anne Liddy Chief Legal Officer 1976 –
Briana Gotlin Vice President of Investor Relations – –
Deanna Wilke Vice President of Corporate Communications – –
Lindsey Little VP & Chief Accounting Officer – –
Paul R. Buckman President of Advanced Circulatory Support & GM of Transcatheter Mitral Valve Replacement 1956 –
Philip Kowalczyk Chief Strategy & Corporate Development Officer – –
Sarah Mohr VP of Legal & Company Secretary – –

Company Peers

Peer analysis pending, check back in 1-2 minutes.